Equities analysts forecast that Apricus Biosciences, Inc (NASDAQ:APRI) will post earnings of ($0.15) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Apricus Biosciences’ earnings. Apricus Biosciences reported earnings per share of ($0.19) during the same quarter last year, which would suggest a positive year-over-year growth rate of 21.1%. The business is scheduled to announce its next earnings report on Tuesday, November 14th.

On average, analysts expect that Apricus Biosciences will report full-year earnings of ($0.81) per share for the current year. For the next year, analysts expect that the company will report earnings of $1.36 per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Apricus Biosciences.

Apricus Biosciences (NASDAQ:APRI) last posted its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01.

APRI has been the topic of a number of research analyst reports. Rodman & Renshaw initiated coverage on shares of Apricus Biosciences in a research report on Wednesday, April 26th. They set a “buy” rating on the stock. Zacks Investment Research downgraded shares of Apricus Biosciences from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Finally, HC Wainwright set a $4.00 price objective on shares of Apricus Biosciences and gave the company a “buy” rating in a research report on Thursday, August 3rd.

COPYRIGHT VIOLATION NOTICE: “Brokerages Anticipate Apricus Biosciences, Inc (NASDAQ:APRI) to Post -$0.15 Earnings Per Share” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/11/brokerages-anticipate-apricus-biosciences-inc-nasdaqapri-to-post-0-15-earnings-per-share.html.

Apricus Biosciences (NASDAQ:APRI) traded down 0.76% during midday trading on Friday, reaching $1.30. 12,713 shares of the company’s stock were exchanged. The company has a market cap of $16.60 million, a price-to-earnings ratio of 2.92 and a beta of 0.57. Apricus Biosciences has a 12-month low of $0.26 and a 12-month high of $4.07. The firm has a 50-day moving average price of $1.18 and a 200 day moving average price of $1.69.

About Apricus Biosciences

Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.

Get a free copy of the Zacks research report on Apricus Biosciences (APRI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Apricus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.